Question of the Month – March 2021 Welcome to your Question of the Month - March 2021 March's question is written by:Clarice Nguyen, MDCombined Pediatrics and Anesthesiology ResidentDepartment of AnesthesiologyDepartment of PediatricsStanford UniversityANDViviana F. Ruiz, MDPediatric Anesthesiology FellowLucile Packard Children's HospitalStanford University An 11-year-old female with a history of precursor B cell acute lymphoblastic leukemia (ALL) is admitted to your pediatric hospital after she was found to have a medullary relapse. The patient has already undergone two rounds of chemotherapy and is now undergoing Chimeric Antigen Receptor (CAR) T-cell therapy. The patient also has a history of chronic peripheral neuropathy and low back pain and is on scheduled hydromorphone. Four days after starting CAR T-cell therapy the patient develops flu-like symptoms, including fever, headache, and severe muscle and joint pain. Blood cultures have been negative to date. You are consulted to help manage the patient’s acute on chronic pain during CAR T-Cell treatment. Which of the following would BEST address this patient’s current pain symptoms? A. The patient’s hydromorphone should be switched to meperidine because meperidine has a less sedating profile B. The patient’s new symptoms are best treated with tocilizumab C. Ibuprofen and acetaminophen should be scheduled around the clock as part of a multimodal pain approach, assuming the patient has normal renal and hepatic function D. The patient’s new symptoms are best treated with corticosteroids None Time's up